A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome

Trial Profile

A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Lambert-Eaton myasthenic syndrome
  • Focus Therapeutic Use
  • Sponsors Catalyst Pharmaceutical Partners
  • Most Recent Events

    • 14 Mar 2017 According to a Biocept Inc. media release, Biocept and Catalyst Pharmaceuticals announce collaboration for the provision of liquid biopsy testing for small cell lung cancer to patients in this trial.
    • 15 Dec 2016 Results from this trial and an NDA re-submission are expected in the second half of 2017, according to a Catalyst Pharmaceuticals Inc. media release.
    • 15 Dec 2016 According to a Catalyst Pharmaceuticals Inc. media release, the first patient has been enrolled into this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top